| Document |
Document Title |
|
WO/2023/112975A1 |
Provided is a lymphocyte function promoter. The lymphocyte function promoter contains at least one selected from the group consisting of a compound represented by general formula (1), a salt thereof, and a solvate of the same.
|
|
WO/2023/111810A1 |
The present disclosure relates to the treatment of cancer and/or cancer-associated disease. Certain aspects relate to the treatment of an individual having cancer or cancer-associated disease by administering to the individual a combinat...
|
|
WO/2023/112992A1 |
The present disclosure provides a safe immunity control method. Provided is a pharmaceutical composition that contains CTLA-4 or a nucleic acid encoding same, or a functional equivalent thereof, or a factor that induces at least one th...
|
|
WO/2023/112678A1 |
Provided is a composition with which it is possible to enhance the percutaneous absorption of a crystalline water-soluble drug without temporarily irritating the skin as with an amphoteric surfactant. The composition of the present dis...
|
|
WO/2023/109784A1 |
The present invention relates to the technical field of biomedicines, and in particular, to a use of an SGLT2 inhibitor in preparation of a drug for preventing and treating male reproductive dysfunction. Research results of the present i...
|
|
WO/2023/114225A1 |
Provided herein is a combination therapy for use in a method of treating mantle cell lymphoma in a patient in need thereof.
|
|
WO/2023/113477A1 |
The present invention provides pharmaceutical combinations comprising (a) a TTK/PLK1 inhibitor (i.e. a compound of formula (I) or a pharmaceutically acceptable salt thereof as defend in the claims) and (b) a taxane anticancer drug or a p...
|
|
WO/2023/108563A1 |
Provided is a pharmaceutical composition for enhancing the anti-tumor effect of an EZH2 inhibitor. The pharmaceutical composition comprises an EZH2 inhibitor and an SD1 inhibitor, wherein the SD1 inhibitor enhances the effect of the EZH2...
|
|
WO/2023/110855A1 |
The present invention provides pea protein and compositions comprising pea protein for use in the prevention and/or treatment of autoimmune arthritis. The invention also provides said compositions for use in combination therapy with an a...
|
|
WO/2023/111173A1 |
The present invention relates to the treatment of resistant leukemia. The inventor studied APL cellular heterogeneity by integrating scRNA-seq and scATAC-seq data obtained from PLZF-RARA transformed promyelocytes treated with RA. Establi...
|
|
WO/2023/114224A1 |
The present disclosure relates to compositions, kits, and methods of treating CNS diseases and disorders using a combination of a muscarinic receptor positive modulator and an NMDA receptor positive allosteric modulator.
|
|
WO/2023/108700A1 |
A biomimetic drug-loaded nanoparticle specifically targeting an inflammatory region after pulsed field ablation and a preparation method. The biomimetic drug-loaded nanoparticle comprises: a drug-loaded liposome and a neutrophil membrane...
|
|
WO/2023/109563A1 |
The present invention relates to a cabazitaxel prodrug anti-tumor preparation, designs and synthesizes a cabazitaxel-fatty alcohol small molecule prodrug containing different fatty alcohol side chains and different connecting chains of g...
|
|
WO/2023/113129A1 |
One aspect relates to a pharmaceutical composition for the prevention or treatment of blood cancer, comprising a surfeit locus protein 4 (SURF4) inhibitor. The composition according to one aspect inhibits SURF4 to increase the expression...
|
|
WO/2023/109290A1 |
The present invention provides an oil composition. The oil comprises a microbial oil and a vegetable oil. Calculating on the basis of the total weight of the composition, the composition comprises at least 0.5 wt% of the oils. The presen...
|
|
WO/2023/104048A1 |
The present invention relates to the field of biomedicine. Disclosed are a brain tumor-targeting polypeptide, a derivative thereof and an application thereof. Specifically disclosed is use of the polypeptide in the preparation of a brain...
|
|
WO/2023/105076A1 |
The present invention relates to the prevention and/or treatment of cancer in a subject, wherein the subject is administered a Gram-negative bacterium in a first treatment phase and a chemotherapy agent in a second treatment phase.
|
|
WO/2023/105227A1 |
There is provided a pharmaceutical or veterinary formulation comprising: (a) a biologically-active agent in admixture with a pharmaceutically- or veterinarily- acceptable extended-release component; (b) an antiinflammatory agent; and (c)...
|
|
WO/2023/107979A1 |
Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise an FGFR kinase inhibitor. Some embodiments comprise combination therapy featuring the FGFR kinase inhibitor with at least one oncology...
|
|
WO/2023/107525A1 |
Disclosed are methods, uses, and combinations for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in patients previously treated with a CDK4 and 6 i...
|
|
WO/2023/104402A1 |
A composition for use in the treatment and/or prevention of COVID-19 disease in a subject, wherein the composition comprises milk protein and the milk protein comprises Serum Protein Concentrate (SPC) and/or Whey Protein Concentrate (WPC...
|
|
WO/2023/103835A1 |
An ophthalmic preparation of a tyrosine kinase inhibitor suitable for eye drop administration is prepared from the following raw materials and adjuvants in parts by weight: active ingredient: 0.5-1.5 parts of a tyrosine kinase inhibitor,...
|
|
WO/2023/104227A1 |
The present invention discloses ginsenosides used alone or in combination with nucleoside/nucleotide analogues for use in the treatment or prophylaxis of chronic hepatitis B virus infections.
|
|
WO/2023/104380A1 |
The present invention relates to nanocontainers for the synergistic transport of lipophilic and hydrophilic active substances or detection reagents. In particular, the nanocontainers according to the invention offer a possibility for the...
|
|
WO/2023/106273A1 |
The present invention addresses the problem of developing a composition having antiviral activity by utilizing the immunological action of intestinal bacteria as well as the action thereof against infection with viruses including influen...
|
|
WO/2023/107697A1 |
Provided herein are methods for treating sickle cell disease comprising administering Compound (I), a modulator of hemoglobin, according to certain dosing regimens.
|
|
WO/2023/105325A1 |
The present invention relates to a composition for oral use comprising sulodexide and one or more flavonoids as active principles, in the treatment of a vascular disease, in particular in the treatment of the chronic venous insufficiency...
|
|
WO/2023/104151A1 |
The present invention relates to a combination of an FAK inhibitor, an anthracycline chemotherapeutic drug, and an immune checkpoint inhibitor to treat tumors. The present invention also relates to a combination of an FAK inhibitor and a...
|
|
WO/2023/105283A1 |
The present invention relates to nucleoside reverse transcriptase inhibitors (NRTI) or their pharmaceutically acceptable salts for use in (a) the treatment of Down syndrome or the consequences thereof or (b) the prevention, inhibition of...
|
|
WO/2023/103137A1 |
An orthoester mixture pharmaceutical excipient, relating to the field of pharmaceutical excipients, and mainly obtained by mixing different orthoester compounds in different proportions or by mixing orthoester compounds with biocompatibl...
|
|
WO/2023/103963A1 |
A cell linker and a cell modified by an agent linked thereto, wherein the agent is conjugated to a phospholipid via a sortase recognition motif, and the phospholipid with the conjugated agent is incorporated into the cell membrane of the...
|
|
WO/2023/104024A1 |
Provided are a mineralized drug-loaded yeast bionic micro-nano robot, and a preparation method therefor and the use thereof. The mineralized drug-loaded yeast bionic micro-nano robot comprises a yeast cell, a biological mineralized nano ...
|
|
WO/2023/108053A1 |
Disclosed herein are compositions for and methods of treating and/or preventing hereditary aortopathies, treating and/or preventing aortic aneurysms, reducing the need for surgical intervention, slowing and/or inhibiting disease progress...
|
|
WO/2023/104021A1 |
A metabolic checkpoint-based human serum albumin nano-drug (IDNPs), and a preparation method therefor and an application thereof. A prodrug molecule IDOi-DON obtained by coupling an indoleamine-2,3-dioxygenase inhibitor (IDOi) and a meta...
|
|
WO/2023/104027A1 |
The present invention provides a yeast immune micro-nano biorobot loaded with blood coagulation drugs, a preparation method therefor and an application thereof. The yeast immune micro-nano biorobot loaded with blood coagulation drugs com...
|
|
WO/2023/104125A1 |
Provided in the present invention are a biomimetic bioengine yeast micro/nanorobot and preparation method therefor. The biomimetic bioengine yeast micro/nanorobot comprises a yeast cell wall having a capsule-shaped structure, drug-loaded...
|
|
WO/2023/106963A1 |
The invention relates to the fields of medicine, pharmacology and the chemical and pharmaceutical industry, and more particularly to a novel crystalline form V of [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimi
din-1-yl]oxol...
|
|
WO/2023/107712A1 |
The present disclosure provides methods of treating or preventing various conditions, diseases, and disorders (e.g., cancer, sepsis/septicemia, pneumonia, fungal infection, immunoparalysis, COVID-19, and myeloablation) in a subject in ne...
|
|
WO/2023/104056A1 |
Provided in the present invention are a yeast bionic immune micro-nano biological robot, and a preparation method therefor and the use thereof. The yeast bionic immune micro-nano biological robot comprises a yeast cell wall microcapsule,...
|
|
WO/2023/104137A1 |
Disclosed are a method for preparing tumor antigen-responsive living cellular nano backpacks and the use thereof. The loading of immune lymphocyte to reduction-responsive albumin nano backpacks is achieved by means of bio-orthogonal coup...
|
|
WO/2023/104058A1 |
The present invention provides a macrophage-based living cell drug-loading system, comprising living cells and drug-loading yeast bionic micro-motors located inside the living cells, wherein the living cells are macrophages, and each dru...
|
|
WO/2023/106964A1 |
The invention relates to the fields of medicine, pharmacology and the chemical and pharmaceutical industry, and more particularly to a novel crystalline form IV of [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimi
din-1-yl]oxo...
|
|
WO/2023/097422A1 |
Disclosed in the present invention is an application of lysine(K)‑specific demethylase 6B (KDM6B) in regulating and controlling the function of a mesenchymal stem cell. WDR5 is a co-binding protein for negatively regulating and control...
|
|
WO/2023/099902A1 |
An ion channel modulator for use in the treatment of cancer and/or metastasis is provided. The ion channel modulator is capable of facilitating ion flow through sodium leak channel (NALCN). A pharmaceutical composition comprising an ion ...
|
|
WO/2023/097980A1 |
Use of a cationic polymer in the preparation of a drug for preventing or treating diseases caused by a toxin produced by intestinal microorganisms or diseases caused by a novel coronavirus infection. The chronic inflammations and various...
|
|
WO/2023/098273A1 |
Disclosed are a target for screening a drug for inhibiting the intestinal fatty acid intake and preventing fatty liver, and the use thereof. According to a knockout mouse experiment, provided in the present invention are a target Soat2 (...
|
|
WO/2023/102091A2 |
The present disclosure provides microbial consortia comprising O. formigenes capable of stable engraftment in the gastrointestinal tract of a subject and methods of using and making the same.
|
|
WO/2023/100745A1 |
The present disclosure relates to: a composition for inducing germinal center migration of activated B-cells, the composition containing a substance that induces expression of CD11b in B-cells; a method for manufacturing the composition;...
|
|
WO/2023/100925A1 |
Provided is an asymmetric cell division inhibitor with which infertility due to aging or the like can be ameliorated. The asymmetric cell division inhibitor includes a spontaneous activation inhibitor that inhibits asymmetric cell divi...
|
|
WO/2023/100691A1 |
The present disclosure relates to providing a substance and a composition that promote the proliferation of epidermal stem cells and are effective in improving wrinkles and barrier function from the viewpoint of maintaining or improving ...
|
